Evidence map›Paper›PMID 31659621›Full record

ArticleJournal of community genetics2020

Survey of primary care physicians' views about breast and ovarian cancer screening for true BRCA1/2 non-carriers.

S Pelletier, G Larouche, J Chiquette, Z El Haffaf, W D Foulkes, P Hamet, J Simard, M Dorval

Open access · bronzeAbstract read
In one paragraph

Article in Journal of community genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

S PelletierOncology Division, CHU de Québec - Université Laval Research Center, 1050, chemin Sainte-Foy, Québec, QC, G1S 4L8, Canada.
G LaroucheOncology Division, CHU de Québec - Université Laval Research Center, 1050, chemin Sainte-Foy, Québec, QC, G1S 4L8, Canada.
J ChiquetteOncology Division, CHU de Québec - Université Laval Research Center, 1050, chemin Sainte-Foy, Québec, QC, G1S 4L8, Canada.
Z El HaffafGenetic Medicine Service, Montreal University Hospital (CHUM), Montréal, QC, Canada.
W D FoulkesDepartment of Medical Genetics, Jewish General Hospital, Montréal, QC, Canada.
P HametResearch Centre, Montreal University Hospital (CHUM), Montréal, QC, Canada.
J SimardOncology Division, CHU de Québec - Université Laval Research Center, 1050, chemin Sainte-Foy, Québec, QC, G1S 4L8, Canada.
M DorvalOncology Division, CHU de Québec - Université Laval Research Center, 1050, chemin Sainte-Foy, Québec, QC, G1S 4L8, Canada. michel.dorval@crchudequebec.ulaval.ca.ORCID http://orcid.org/0000-0002-3207-8211
Université Laval · CACentre Hospitalier de l’Université de Montréal · CACentre Intégré de Santé et Services Sociaux de Chaudière-Appalache · CAJewish General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite some controversy, true BRCA1/2 non-carriers are generally considered to be at an average risk for breast and ovarian cancer. Primary care physicians are then expected to encourage their non-carrier patients to adopt cancer screening practices appropriate to women of the same age in the general population. This study aimed to describe breast and ovarian cancer screening recommendations that primary care physicians would consider advisable for young true BRCA1/2 non-carriers. One hundred thirty-four family physicians and 123 gynecologists (response rate 45%) completed a cross-sectional mailed survey administered in the Province of Quebec, Canada. The survey included questions about basic genetic knowledge and screening recommendations for two fictitious cases (< 40 years), one carrier and one non-carrier, from a BRCA1/2 mutation-positive family. Screening exams considered advisable did not differ significantly between family physicians and gynecologists. More than 75% of physicians considered the cancer risks of true non-carriers to be comparable with that of the general population and 14% to be a little higher. Still, 53% would prescribe a biennial and or even an annual (27%) mammography to a non-carrier woman before the recommended starting age. Physician considerations of non-carriers' expectations or requests for screening were associated with more screening prescriptions. More than half of primary care physicians would recommend more mammography screenings than expected for a young true BRCA1/2 non-carrier. Personalized cancer risk assessment may help primary care physicians tailor screening of women from BRCA1/2 mutation-positive families and allow these women to make more informed choices regarding cancer risk management options.

Indexed as

BRCA1BRCA2Genetic screeningHereditary cancer syndromesPhysicians’ practice patternsSurvey

Identifiers

PMID31659621
PMCPMC7062973
OpenAlexW2982310720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.